Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Free Report) - Equities researchers at KeyCorp issued their Q1 2027 earnings per share estimates for Maravai LifeSciences in a report released on Wednesday, November 11th. KeyCorp analyst P. Knight forecasts that the company will post earnings per share of $0.00 for the quarter. KeyCorp has an "Overweight" rating and a $11.00 price target on the stock. The consensus estimate for Maravai LifeSciences' current full-year earnings is ($0.16) per share. KeyCorp also issued estimates for Maravai LifeSciences' Q2 2027 earnings at ($0.04) EPS, Q4 2027 earnings at ($0.05) EPS and FY2028 earnings at ($0.13) EPS.
A number of other analysts have also weighed in on the stock. TD Cowen started coverage on shares of Maravai LifeSciences in a research note on Monday, October 5th. They set a "buy" rating and a $9.00 target price on the stock. UBS Group lifted their price target on shares of Maravai LifeSciences from $2.50 to $8.00 and gave the stock a "neutral" rating in a research note on Wednesday, September 9th. Wall Street Zen upgraded shares of Maravai LifeSciences from a "hold" rating to a "buy" rating in a report on Saturday, November 7th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Maravai LifeSciences in a report on Wednesday, August 26th. Finally, Wells Fargo & Company increased their price objective on shares of Maravai LifeSciences from $5.50 to $6.50 and gave the company an "overweight" rating in a research report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Maravai LifeSciences has an average rating of "Moderate Buy" and a consensus target price of $8.10.
Read Our Latest Research Report on Maravai LifeSciences
Maravai LifeSciences Stock Performance
Shares of MRVI opened at $7.40 on Tuesday. Maravai LifeSciences has a 1 year low of $2.80 and a 1 year high of $9.42. The stock has a market capitalization of $1.92 billion, a PE ratio of -17.21 and a beta of 0.61. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.98 and a current ratio of 4.66. The stock has a 50-day simple moving average of $7.40 and a 200-day simple moving average of $5.44.
Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last released its earnings results on Wednesday, November 4th. The company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.03. The firm had revenue of $45.85 million during the quarter, compared to analysts' expectations of $43.56 million. Maravai LifeSciences had a negative return on equity of 12.44% and a negative net margin of 30.83%.
Institutional Trading of Maravai LifeSciences
A number of institutional investors have recently bought and sold shares of MRVI. Goldman Sachs Group Inc. raised its position in shares of Maravai LifeSciences by 24.5% during the 3rd quarter. Goldman Sachs Group Inc. now owns 2,043,668 shares of the company's stock worth $15,654,000 after acquiring an additional 402,371 shares in the last quarter. Entropy Technologies LP acquired a new position in Maravai LifeSciences in the third quarter valued at approximately $155,000. Marshall Wace LLP increased its stake in Maravai LifeSciences by 38.2% in the third quarter. Marshall Wace LLP now owns 2,034,070 shares of the company's stock valued at $15,581,000 after purchasing an additional 562,593 shares during the last quarter. Caxton Associates LLP increased its stake in Maravai LifeSciences by 71.8% in the third quarter. Caxton Associates LLP now owns 193,290 shares of the company's stock valued at $1,481,000 after purchasing an additional 80,811 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in Maravai LifeSciences during the third quarter worth approximately $5,259,000. 50.25% of the stock is owned by hedge funds and other institutional investors.
Maravai LifeSciences Company Profile
(
Get Free Report)
Maravai LifeSciences provides products and services used by biotechnology and pharmaceutical companies in the development and production of therapeutics, vaccines, and other biologic products. Its offerings include specialized nucleic acid materials and analytical testing services that support research, manufacturing, and quality control. Through TriLink BioTechnologies, the company supplies modified nucleotides, custom RNA and DNA, and related materials used in applications such as messenger RNA research and production.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Maravai LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maravai LifeSciences wasn't on the list.
While Maravai LifeSciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.